← Back to patent-cliff list
RO-7568282
Tier C — Watch / tradeRO-7568282
F. Hoffmann-La Roche
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：NLRP3
Indications (approved)：Parkinson's disease, Alzheimer's disease
Regional status
US
Phase II
2026-09-20
EU
-
China
Phase II
2026-09-20
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of RO-7568282?
Approved indications include: Parkinson's disease, Alzheimer's disease.
When does the RO-7568282 patent expire?
No public expiry year is available for RO-7568282 yet; this page updates once verified.
How do I get a quote for RO-7568282 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29